Hypoglycemia events in T1D patients will be monitored using a continuous glucose monitor. Credit: Click and Photo via Shutterstock.

The US Food and Drug Administration (FDA) has granted clearance for Zucara Therapeutics’ investigational new drug (IND) application for the Phase IIa ZONE clinical trial of ZT-01 to prevent night-time (nocturnal) hypoglycemia in patients with type 1 diabetes (T1D).

The effect of ZT-01 on the frequency of nocturnal hypoglycemia in these patients will be assessed in the multiple-dose, crossover, double-blind, multi-centre, randomised, placebo-controlled study.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Three doses of ZT-01, or a placebo, will be self-administered by the subjects every evening before bed for four weeks.

Hypoglycemia events in T1D patients will be monitored using a continuous glucose monitor.

The rate of nocturnal hypoglycemic events will be measured as the primary endpoint while adverse events and time spent in hypoglycemia against placebo will be the study’s secondary endpoints.

The first patient of the Phase IIa study is expected to be dosed in the third quarter of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Zucara Therapeutics clinical and regulatory affairs director Susan Peers said: “We are thrilled to have reached this important milestone and eager to initiate our planned Phase II trial for the prevention of nocturnal hypoglycemia, a frequent occurrence for people with insulin-dependent diabetes that is a significant cause of anxiety for both patients and their loved ones.

“Having demonstrated proof-of-concept and ZT-01’s ability to significantly increase glucagon release in patients with T1D, we are looking forward to showing we can prevent potentially dangerous low blood glucose levels overnight.

“We are excited to take the next step in developing what could be the first therapeutic available to prevent night-time hypoglycemia.”